Progress in intravenous thrombolytic therapy for acute stroke

JAMA Neurology

Volumn 72, Issue 8, 2015, Pages 928-934

  Marshall, Randolph S ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ALTEPLASE; ARGATROBAN; EPTIFIBATIDE; STREPTOKINASE; TENECTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AMINO ACID SUBSTITUTION; BRAIN ISCHEMIA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HISTORY OF MEDICINE; HUMAN; INDUCED HYPOTHERMIA; MICROBUBBLE; NEUROIMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREND STUDY; ULTRASOUND THERAPY; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; STROKE; TIME;

ADMINISTRATION, INTRAVENOUS; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84938916652     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.0835     Document Type: Review

References (34)

1. Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587.
2. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med. 1933;58(4):485-502.
3. Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J Am Med Assoc. 1958;167(14):1705-1709.
4. Fujishima M, Omae T, Tanaka K, Iino K, Matsuo O, Mihara H. Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction. Angiology. 1986;37(7):487-498.
5. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke: the Multicentre Acute Stroke Trial Italy (MAST-I) group. Lancet. 1995;346 (8989):1509-1514.
6. Thrombolytic therapy with streptokinase in acute ischemic stroke: the Multicenter Acute Stroke Trial Europe study group. N Engl J Med. 1996;335 (3):145-150.
7. Terashi A, Kobayashi Y, Katayama Y, Inamura K, Kazama M, Abe T. Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis. Semin Thromb Hemost. 1990;16(3):236-241.
8. Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for stroke, part I: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23(5):632-640.
9. Haley EC Jr, Levy DE, Brott TG, et al. Urgent therapy for stroke, part II: pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23(5):641-645.
10. Freeman R, Niego B, Croucher DR, Pedersen LO, Medcalf RL. t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions. Brain Res. 2014;1565:63-73.
11. Wang L, Fan W, Cai P, et al. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. Ann Neurol. 2013;73(2):189-198.
12. Gomaraschi M, Ossoli A, Vitali C, et al. Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase. Biochem Pharmacol. 2013;85(4):525-530.
13. Micieli G, Marcheselli S, Tosi PA. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag. 2009;5 (1):397-409.
14. Bringmann P, Gruber D, Liese A, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem. 1995;270(43): 25596-25603.
15. Hacke W, Albers G, Al-Rawi Y, et al; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36(1):66-73.
16. Furlan AJ, Eyding D, Albers GW, et al; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37(5):1227-1231.
17. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8 (2):141-150.
18. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366 (12):1099-1107.
19. Logallo N, Kvistad CE, Nacu A, et al. The Norwegian Tenecteplase Stroke Trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol. 2014;14:106.
20. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA. 1999;282(21): 2019-2026.
21. De Silva DA, Fink JN, Christensen S, et al; Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators. Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET). Stroke. 2009;40(8):2872-2874.
22. Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.
23. Hacke W, Donnan G, Fieschi C, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774.
24. Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke. 1981;12(6):723-725.
25. Davis SM, Donnan GA, Butcher KS, Parsons M. Selection of thrombolytic therapy beyond 3 hours using magnetic resonance imaging. Curr Opin Neurol. 2005;18(1):47-52.
26. Heiss WD, Sobesky J, Smekal Uv, et al. Probability of cortical infarction predicted by flumazenil binding and diffusion-weighted imaging signal intensity: a comparative positron emission tomography/magnetic resonance imaging study in early ischemic stroke. Stroke. 2004;35(8):1892-1898.
27. Ma H, Wright P, Allport L, et al. Salvage of the PWI/DWI mismatch up to 48 h from stroke onset leads to favorable clinical outcome. Int J Stroke. 2014.
28. Kidwell CS, Jahan R, Gornbein J, et al; MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368(10):914-923.
29. Markus R, Reutens DC, Kazui S, et al. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain. 2004;127(Pt 6):1427-1436.
30. Liebeskind DS, Sanossian N. How well do blood flow imaging and collaterals on angiography predict brain at risk? Neurology. 2012;79(13)(suppl 1):S105-S109.
31. Saver JL, Goyal M, Bonafe A, et al; SWIFT PRIME Investigators. Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. Int J Stroke. 2015;10(3):439-448.
32. Goyal M, Demchuk AM, Menon BK, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019-1030.
33. Campbell BC, Mitchell PJ, Kleinig TJ, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009-1018.
34. Berkhemer OA, Fransen PS, Beumer D, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11-20.